These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 38975713)
21. Defining the antigen-specific T-cell response to vaccination and poly(I:C)/TLR3 signaling: evidence of enhanced primary and memory CD8 T-cell responses and antitumor immunity. Salem ML; Kadima AN; Cole DJ; Gillanders WE J Immunother; 2005; 28(3):220-8. PubMed ID: 15838378 [TBL] [Abstract][Full Text] [Related]
22. T Cells Modified with CD70 as an Alternative Cellular Vaccine for Antitumor Immunity. Lee SE; Shin AR; Sohn HJ; Cho HI; Kim TG Cancer Res Treat; 2020 Jul; 52(3):747-763. PubMed ID: 32065848 [TBL] [Abstract][Full Text] [Related]
23. Engineered Bacteriophage-Based Lei L; Yan J; Xin K; Li L; Sun Q; Wang Y; Chen T; Wu S; Shao J; Liu B; Chen X ACS Nano; 2024 May; 18(19):12194-12209. PubMed ID: 38689426 [No Abstract] [Full Text] [Related]
24. New generation of DNA-based immunotherapy induces a potent immune response and increases the survival in different tumor models. Lopes A; Bastiancich C; Bausart M; Ligot S; Lambricht L; Vanvarenberg K; Ucakar B; Gallez B; Préat V; Vandermeulen G J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33795383 [TBL] [Abstract][Full Text] [Related]
26. Helper function of memory CD8+ T cells: heterologous CD8+ T cells support the induction of therapeutic cancer immunity. Nakamura Y; Watchmaker P; Urban J; Sheridan B; Giermasz A; Nishimura F; Sasaki K; Cumberland R; Muthuswamy R; Mailliard RB; Larregina AT; Falo LD; Gooding W; Storkus WJ; Okada H; Hendricks RL; Kalinski P Cancer Res; 2007 Oct; 67(20):10012-8. PubMed ID: 17942935 [TBL] [Abstract][Full Text] [Related]
27. Antitumor activity of a self-adjuvanting glyco-lipopeptide vaccine bearing B cell, CD4+ and CD8+ T cell epitopes. Bettahi I; Dasgupta G; Renaudet O; Chentoufi AA; Zhang X; Carpenter D; Yoon S; Dumy P; BenMohamed L Cancer Immunol Immunother; 2009 Feb; 58(2):187-200. PubMed ID: 18584174 [TBL] [Abstract][Full Text] [Related]
28. Significant anti-tumour activity of adoptively transferred T cells elicited by intratumoral dendritic cell vaccine injection through enhancing the ratio of CD8(+) T cell/regulatory T cells in tumour. Song S; Zhang K; You H; Wang J; Wang Z; Yan C; Liu F Clin Exp Immunol; 2010 Oct; 162(1):75-83. PubMed ID: 20735440 [TBL] [Abstract][Full Text] [Related]
29. Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen. Xia D; Zheng S; Zhang W; He L; Wang Q; Pan J; Zhang L; Wang J; Cao X J Mol Med (Berl); 2003 Sep; 81(9):585-96. PubMed ID: 12937899 [TBL] [Abstract][Full Text] [Related]
31. PLGA micro/nanoparticle vaccination elicits non-tumor antigen specific resident memory CD8 Li P; Zhai Z; Fang J; Wang R; Li W; Wang B; Wang J; Zhu J; Bing F; Pan Q; Gao C; Lu S Nanoscale; 2024 Jun; 16(25):12149-12162. PubMed ID: 38833269 [TBL] [Abstract][Full Text] [Related]
32. In situ tumor vaccination with interleukin-12-encapsulated biodegradable microspheres: induction of tumor regression and potent antitumor immunity. Egilmez NK; Jong YS; Sabel MS; Jacob JS; Mathiowitz E; Bankert RB Cancer Res; 2000 Jul; 60(14):3832-7. PubMed ID: 10919657 [TBL] [Abstract][Full Text] [Related]
33. Adenovirus expressing both thymidine kinase and soluble PD1 enhances antitumor immunity by strengthening CD8 T-cell response. Shin SP; Seo HH; Shin JH; Park HB; Lim DP; Eom HS; Bae YS; Kim IH; Choi K; Lee SJ Mol Ther; 2013 Mar; 21(3):688-95. PubMed ID: 23337984 [TBL] [Abstract][Full Text] [Related]
34. Extending antigen release from particulate vaccines results in enhanced antitumor immune response. Kapadia CH; Tian S; Perry JL; Sailer D; Christopher Luft J; DeSimone JM J Control Release; 2018 Jan; 269():393-404. PubMed ID: 29146244 [TBL] [Abstract][Full Text] [Related]
35. CD4+ T cells are able to promote tumor growth through inhibition of tumor-specific CD8+ T-cell responses in tumor-bearing hosts. den Boer AT; van Mierlo GJ; Fransen MF; Melief CJ; Offringa R; Toes RE Cancer Res; 2005 Aug; 65(15):6984-9. PubMed ID: 16061684 [TBL] [Abstract][Full Text] [Related]
36. Vaccine therapy of established tumors in the absence of autoimmunity. Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742 [TBL] [Abstract][Full Text] [Related]
37. Turning Threat to Therapy: A Nanozyme-Patch in Surgical Bed for Convenient Tumor Vaccination by Sustained In Situ Catalysis. Wang Z; Dong M; Pan Y; Zhang L; Lei H; Zheng Y; Shi Y; Liu S; Li N; Wang Y Adv Healthc Mater; 2024 May; 13(13):e2304384. PubMed ID: 38301259 [TBL] [Abstract][Full Text] [Related]
38. TLR9 agonist enhances radiofrequency ablation-induced CTL responses, leading to the potent inhibition of primary tumor growth and lung metastasis. Xu A; Zhang L; Yuan J; Babikr F; Freywald A; Chibbar R; Moser M; Zhang W; Zhang B; Fu Z; Xiang J Cell Mol Immunol; 2019 Oct; 16(10):820-832. PubMed ID: 30467420 [TBL] [Abstract][Full Text] [Related]
39. Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen. Wculek SK; Amores-Iniesta J; Conde-Garrosa R; Khouili SC; Melero I; Sancho D J Immunother Cancer; 2019 Apr; 7(1):100. PubMed ID: 30961656 [TBL] [Abstract][Full Text] [Related]